Electronic comment system
This article was originally published in The Tan Sheet
Executive Summary
FDA will no longer accept electronic comments through its Web site beginning Jan. 15. Rather, it will accept electronic comments only through the Federal Dockets Management System - a full-featured management system and "one-stop site to search, view and download documents," the agency says in notice scheduled to appear in the Jan. 14 Federal Register. The switch is part of the president's e-rulemaking initiative. Public can access the system at 1http://www.Regulations.gov. The agency will move all dockets managed in the current system to the new system in the next few months...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.